The 15th Pediatric and Wildtype GIST Clinic was recently held at the National Institute of Health in Bethesda, Maryland on July 5 - 7, 2017. The Clinic is a collaborative effort between clinicians and [...]
A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]
We love our donors! All we need is LOVE Over the last 16 years, we have worked toward increasing patient survival and ensuring a better quality of life for GIST survivors. I [...]
Rare Disease Day is celebrated on the last day of February each year. The day is celebrated in order to bring attention to the general public and decision makers about rare diseases and how [...]
The recent announcement of the research collaboration between the Life Raft Group and Columbia University Medical Center, NewYork Presbyterian has garnered media attention. Recent articles have been feature in both Cure Today and GenomeWeb. [...]
New York, NY and Wayne, NJ - January 12, 2017 Columbia University Medical Center, NewYork-Presbyterian and the Life Raft Group (LRG), a patient advocacy organization specializing in GIST cancer, announced today that they have [...]
In a pre-print electronic publication of the July 7, 2016 edition of Clinical Cancer Research, a team of Italian researchers examined the link between “Quadruple-Negative” GISTs (those that do not exhibit KIT, PDGFRA, or BRAF [...]
For patients who have recently been diagnosed with cancer, donating a tissue sample is probably the last thing on their minds. But it’s an important consideration. Researchers often rely on donated tissue to advance [...]
David Josephy On behalf of The Life Raft Group USA and Life Raft Group Canada, I attended the Sarcoma & GIST 2016 meeting organized by the European Society for Medical Oncology (ESMO) [...]
In a recent release from the Translational Genomics Research Institute (TGen), it was reported that researchers have discovered that by analyzing circulating tumor DNA (ctDNA) through liquid biopsy that a patient's cancer can be tracked [...]
